natgillin/translations-raw huggingface dataset:
In order to ensure a smooth progression from the existing formulae of cosmetic products to formulae which comply with the requirements laid down in this Directive, it is necessary to provide for appropriate transitional periods.
Za zagotovitev nemotenega prehoda iz obstoječih sestav kozmetičnih izdelkov na sestave, skladne z zahtevami, določenimi v tej direktivi, je treba določiti ustrezno prehodno obdobje.
Part 1 of Annex III to Directive 76/768/EEC is amended in accordance with the Annex to this Directive.
Del 1 Priloge III k Direktivi 76/768/EGS se spremeni v skladu s Prilogo k tej direktivi.
Member States shall take all necessary measures to ensure that products which fail to comply with this Directive are not sold or disposed of to the final consumer after 16 February 2009.
Države članice sprejmejo potrebne ukrepe, da se od 16. februarja 2009 izdelki, ki niso v skladu s to direktivo, ne prodajajo ali drugače dajejo na voljo končnemu porabniku.
Member States shall adopt and publish, by 16 August 2008 at the latest, the laws, regulations and administrative provisions necessary to comply with this Directive.
Države članice najpozneje do 16. avgusta 2008 sprejmejo in objavijo zakone in druge predpise, potrebne za uskladitev s to direktivo.
They shall apply those provisions from 16 November 2008.
Navedene predpise uporabljajo od 16. novembra 2008.
Done at Brussels, 15 February 2008.
V Bruslju, 15. februarja 2008.
Directive as last amended by Commission Directive 2007/67/EC (OJ L 305, 23.11.2007, p. 22).
Direktiva, kakor je bila nazadnje spremenjenja z Direktivo Komisije 2007/67/ES (UL L 305, 23.11.2007, str. 22).
Directive as last amended by Directive 2006/121/EC of the European Parliament and of the Council (OJ L 396, 30.12.2006, p. 850), as corrected by OJ L 136, 29.5.2007, p. 281.
Direktiva, kakor je bila nazadnje spremenjena z Direktivo 2006/121/ES Evropskega parlamenta in Sveta (UL L 396, 30.12.2006, str. 850), kakor je bila popravljena v UL L 136, 29.5.2007, str. 281.
In Part 1 of Annex III to Directive 76/768/EEC the following entry for glyoxal is added:
V delu 1 Priloge III k Direktivi 76/768/EGS se za glioksal doda naslednji vnos:
CAS No 107-22-2
št. CAS 107-22-2
EINECS No 203-474-9
št. Einecs 203-474-9
Commission Directive 2008/15/EC
Direktiva Komisije 2008/15/ES
amending Directive 98/8/EC of the European Parliament and of the Council to include clothianidin as an active substance in Annex I thereto
o spremembi Direktive 98/8/ES Evropskega parlamenta in Sveta za vključitev klotianidina kot aktivne snovi v Prilogo I k Direktivi
That list includes clothianidin.
Navedeni seznam vključuje klotianidin.
Pursuant to Regulation (EC) No 2032/2003, clothianidin has been evaluated in accordance with Article 11(2) of Directive 98/8/EC for use in product type 8, wood preservatives, as defined in Annex V to Directive 98/8/EC.
Na podlagi Uredbe (ES) št. 2032/2003 je bila v skladu s členom 11(2) Direktive 98/8/ES opravljena presoja klotianidina glede uporabe v 8. vrsti izdelkov, pripravkih za zaščito lesa, kot je opredeljena v Prilogi V k Direktivi 98/8/ES.
Germany was designated as Rapporteur Member State and submitted the competent authority report, together with a recommendation, to the Commission on 15 December 2005 in accordance with Article 10(5) and (7) of Regulation (EC) No 2032/2003.
Nemčija, ki je bila imenovana za državo članico poročevalko, je 15. decembra 2005 v skladu s členom 10(5) in (7) Uredbe (ES) št. 2032/2003 Komisiji poslala poročilo pristojnega organa in priporočilo.
The review of clothianidin did not reveal any open questions or concerns to be addressed by the Scientific Committee on Health and Environmental Risks.
Med pregledom klotianidina se niso pojavila nobena odprta vprašanja ali razlogi za zaskrbljenost, ki bi jih moral obravnavati Znanstveni odbor za zdravstvena in okoljska tveganja.
It appears from the examinations made that biocidal products used as wood preservatives and containing clothianidin may be expected to satisfy the requirements laid down in Article 5 of Directive 98/8/EC.
Preiskave so pokazale, da je za biocidne pripravke, ki se uporabljajo kot pripravki za zaščito lesa in vsebujejo klotianidin, pričakovati, da izpolnjujejo zahteve iz člena 5 Direktive 98/8/ES.
However, unacceptable risks were identified for uses of treated wood outdoors but not in ground or water contact.
Kljub temu so bila ugotovljena nesprejemljiva tveganja za uporabo lesa, obdelanega s tem pripravkom, na prostem, vendar ne v stiku s tlemi ali vodo.
It is therefore appropriate to include clothianidin in Annex I to Directive 98/8/EC, in order to ensure that in all Member States authorisations for biocidal products used as wood preservatives and containing clothianidin can be granted, modified, or cancelled in accordance with Article 16(3) of Directive 98/8/EC.
Zato je primerno vključiti klotianidin v Prilogo I k Direktivi 98/8/ES, da se v vseh državah članicah v skladu s členom 16(3) Direktive 98/8/ES zagotovi, da se izdajo, spremenijo ali razveljavijo dovoljenja za biocidne pripravke, ki se uporabljajo kot pripravki za zaščito lesa in vsebujejo klotianidin.
Authorisations for products to be used for the treatment of wood that will be used outdoors will require the submission of data in order to demonstrate that the products can be used without unacceptable risks to the environment.
Za izdajo dovoljenj za pripravke, ki se uporabljajo za obdelavo lesa, namenjenega uporabi na prostem, je treba predložiti podatke, ki dokazujejo, da se lahko pripravki uporabljajo brez nesprejemljivih tveganj za okolje.
In the light of the findings of the assessment report, it is appropriate to require that risk mitigation measures are applied at product authorisation level to products containing clothianidin and used as wood preservatives to ensure that risks be reduced to an acceptable level in accordance with Article 5 and Annex VI of Directive 98/8/EC.
Glede na ugotovitve poročila o oceni je primerno zahtevati, da se v skladu s členom 5 in Prilogo VI k Direktivi 98/8/ES pri izdaji dovoljenj za pripravke, ki vsebujejo klotianidin in se uporabljajo za zaščito lesa, uporabijo ukrepi za zmanjšanje tveganja, ki zagotavljajo, da se tveganja zmanjšajo na sprejemljivo raven.
Special attention should be paid to measures aimed at protecting the soil, surface water and groundwater compartments since unacceptable risks in these compartments have been identified during the evaluation of the submitted dossier from certain uses.
Posebno pozornost je treba posvetiti ukrepom za zaščito tal, površinskih voda in predelov s podzemno vodo, saj so bila med ocenjevanjem predložene dokumentacije o nekaterih vrstah uporabe za ta področja ugotovljena nesprejemljiva tveganja.
Not all potential uses have been evaluated at the Community level.
Na ravni Skupnosti ni bila opravljena presoja vseh možnosti uporabe.
It is therefore appropriate that Member States assess those risks to the compartments and populations that have not been representatively addressed in the Community level risk assessment and, when granting product authorisations, ensure that appropriate measures are taken or specific conditions imposed in order to mitigate the identified risks to acceptable levels.
Zato je primerno, da države članice ocenijo tveganja za predele in prebivalce, ki niso bili reprezentativno obravnavani v oceni tveganja na ravni Skupnosti, ter da pri izdaji dovoljenj za pripravke zagotovijo, da se sprejmejo ustrezni ukrepi ali naložijo posebni pogoji za zmanjšanje ugotovljenih tveganj na sprejemljivo raven.
It is important that the provisions of this Directive be applied simultaneously in all the Member States in order to ensure equal treatment of biocidal products on the market containing the active substance clothianidin and also to facilitate the proper operation of the biocidal products market in general.
Pomembno je, da se določbe te direktive uporabljajo hkrati v vseh državah članicah, da se zagotovi enako ravnanje z biocidnimi pripravki na trgu, ki vsebujejo aktivno snov klotianidin, in da se omogoči ustrezno delovanje trga biocidnih pripravkov na sploh.
A reasonable period should be allowed to elapse before an active substance is included in Annex I to Directive 98/8/EC in order to permit Member States and the interested parties to prepare themselves to meet the new requirements entailed and to ensure that applicants who have prepared dossiers can benefit fully from the 10-year period of data protection, which, in accordance with Article 12(1)(c)(ii) of Directive 98/8/EC, starts from the date of inclusion.
Pred vključitvijo aktivne snovi v Prilogo I k Direktivi 98/8/ES je treba zagotoviti ustrezno obdobje, ki bo omogočilo državam članicam in zainteresiranim stranem, da se pripravijo na izpolnjevanje novih zahtev, in prijaviteljem, ki so pripravili dokumentacijo, da lahko povsem izkoristijo desetletno obdobje za varstvo podatkov, ki se v skladu s členom 12(1)(c)(ii) Direktive 98/8/ES začne z dnem vključitve.
After inclusion, Member States should be allowed a reasonable period to implement Article 16(3) of Directive 98/8/EC, and in particular, to grant, modify or cancel authorisations of biocidal products in product type 8 containing clothianidin to ensure that they comply with Directive 98/8/EC.
Državam članicam je treba po vključitvi zagotoviti ustrezno obdobje za izvedbo člena 16(3) Direktive 98/8/ES in zlasti za izdajo, spremembo ali razveljavitev dovoljenj za biocidne pripravke v 8. vrsti izdelkov, ki vsebujejo klotianidin, da se zagotovi njihova skladnost z Direktivo 98/8/ES.
Member States shall adopt and publish, by 31 January 2009 at the latest, the laws, regulations and administrative provisions necessary to comply with this Directive.
Države članice sprejmejo in objavijo zakone in druge predpise, potrebne za uskladitev s to direktivo, najpozneje do 31. januarja 2009.
They shall apply those provisions from 1 February 2010.
Navedene predpise uporabljajo od 1. februarja 2010.
Done at Brussels, 15 February 2008.
V Bruslju, 15. februarja 2008
Directive as last amended by Commission Directive 2007/70/EC (OJ L 312, 30.11.2007, p. 26).
Direktiva, kakor je bila nazadnje spremenjena z Direktivo Komisije 2007/70/ES (UL L 312, 30.11.2007, str. 26).
The following entry ‘No 3’ is inserted in Annex I to Directive 98/8/EC:
V Prilogo I k Direktivi 98/8/ES se vstavi naslednji vnos „št. 3“:
(except for products containing more than one active substance, for which the deadline to comply with Article 16(3) shall be the one set out in the last of the inclusion decisions relating to its active substances)
(razen za pripravke, ki vsebujejo več kot eno aktivno snov, za katere je rok za uskladitev s členom 16(3) enak roku, določenemu v zadnji odločbi o vključitvi njihovih aktivnih snovi)
Product type
Vrsta izdelkov
EC No: 433-460-1
Št. ES: 433-460-1
CAS No: 210880-92-5
št. CAS: 210880-92-5
1 February 2010
februar 2010
31 January 2012
januar 2012
31 January 2020
januar 2020
When assessing, in accordance with Article 5 and Annex VI, the application for authorisation of a product, Member States shall assess those use/exposure scenarios and/or populations that have not been representatively addressed in the Community level risk assessment and that may be exposed to the product.
Države članice pri ocenjevanju vlog za izdajo dovoljenja za pripravek v skladu s členom 5 in Prilogo VI ocenijo tiste scenarije uporabe oziroma izpostavljenosti in/ali osebe, ki niso bili reprezentativno obravnavani v oceni tveganja na ravni Skupnosti in bi lahko bili izpostavljeni pripravku.
When granting product authorisation, Member States shall assess the risks and subsequently ensure that appropriate measures are taken or specific conditions imposed in order to mitigate the identified risks.
Pri izdaji dovoljenj za pripravke države članice ocenijo tveganja in nato zagotovijo, da se sprejmejo ustrezni ukrepi ali naložijo posebni pogoji za zmanjšanje ugotovljenih tveganj.
Product authorisation can only be granted where the application demonstrates that risks can be reduced to acceptable levels.
Dovoljenje za pripravek se lahko izda samo v primeru, ko vloga za izdajo dovoljenja pokaže, da je tveganja mogoče zmanjšati na sprejemljivo raven.
In view of the risk identified for the soil, surface water and groundwater compartments, products cannot be authorised for the treatment of wood that will be used outdoors unless data is submitted to demonstrate that the product will meet the requirements of Article 5 and Annex VI, if necessary by the application of appropriate risk mitigation measures.
Zaradi ugotovljenih tveganj za tla, površinske vode in predele s podzemno vodo se dovoljenja ne morejo izdati za pripravke za obdelavo lesa, namenjenega uporabi na prostem, razen če predloženi podatki ne pokažejo, da je pripravek v skladu z zahtevami člena 5 in Priloge VI, po potrebi z uporabo ustreznih ukrepov za zmanjšanje tveganja.
In particular, labels and/or safety-data sheets of products authorised for industrial use indicate that freshly treated timber must be stored after treatment on impermeable hard standing to prevent direct losses to soil and that any losses must be collected for reuse or disposal.’
Zlasti na oznakah in/ali varnostnih listih pripravkov, katerih uporaba je dovoljena v industriji, se navede, da je treba sveže obdelani les po obdelavi hraniti na neprepustni trdni podlagi, da se prepreči neposredno spiranje pripravkov v tla, in da se mora omogočiti njihovo zbiranje za ponovno uporabo ali odstranjevanje.“
Commission Directive 2008/16/EC
Direktiva Komisije 2008/16/ES
amending Directive 98/8/EC of the European Parliament and of the Council to include etofenprox as an active substance in Annex I thereto
o spremembi Direktive 98/8/ES Evropskega parlamenta in Sveta za vključitev etofenproksa kot aktivne snovi v Prilogo I k Direktivi
That list includes etofenprox.
Navedeni seznam vključuje etofenproks.
Pursuant to Regulation (EC) No 2032/2003, etofenprox has been evaluated in accordance with Article 11(2) of Directive 98/8/EC for use in product type 8, wood preservatives, as defined in Annex V to Directive 98/8/EC.
Na podlagi Uredbe (ES) št. 2032/2003 je bila v skladu s členom 11(2) Direktive 98/8/ES opravljena presoja etofenproksa glede uporabe v 8. vrsti izdelkov, pripravkih za zaščito lesa, kot je opredeljena v Prilogi V k Direktivi 98/8/ES.
Austria was designated as Rapporteur Member State and submitted the competent authority report, together with a recommendation, to the Commission on 11 October 2005 in accordance with Article 10(5) and (7) of Regulation (EC) No 2032/2003.
Avstrija, ki je bila imenovana za državo članico poročevalko, je 11. oktobra 2005 v skladu s členom 10(5) in (7) Uredbe (ES) št. 2032/2003 Komisiji poslala poročilo pristojnega organa in priporočilo.
In accordance with Article 11(4) of Regulation (EC) No 2032/2003, the findings of the review were incorporated, within the Standing Committee on Biocidal Products on 21 June 2006, in an assessment report.
V skladu s členom 11(4) Uredbe (ES) št. 2032/2003 je Stalni odbor za biocidne pripravke 21. junija 2006 ugotovitve vključil v poročilo o oceni.
The review of etofenprox did not reveal any open questions or concerns to be addressed by the Scientific Committee on Health and Environmental Risks.
Med pregledom etofenproksa se niso pojavila odprta vprašanja ali razlogi za zaskrbljenost, ki bi jih moral obravnavati Znanstveni odbor za zdravstvena in okoljska tveganja.
It appears from the examinations made that biocidal products used as wood preservatives and containing etofenprox may be expected to satisfy the requirements laid down in Article 5 of Directive 98/8/EC.
Preiskave so pokazale, da je za biocidne pripravke, ki se uporabljajo kot pripravki za zaščito lesa in vsebujejo etofenproks, pričakovati, da izpolnjujejo zahteve iz člena 5 Direktive 98/8/ES.
However, acceptable risks to human health were only identified for seasonal and intermittent (up to three months per year) use.
Sprejemljiva tveganja za zdravje ljudi so bila ugotovljena le za sezonsko uporabo in uporabo s prekinitvami (do 3 mesece letno).
It is therefore appropriate to include etofenprox in Annex I to Directive 98/8/EC, in order to ensure that in all Member States authorisations for biocidal products used as wood preservatives and containing etofenprox can be granted, modified, or cancelled in accordance with Article 16(3) of Directive 98/8/EC.
Zato je primerno vključiti etofenproks v Prilogo I k Direktivi 98/8/ES, da se v vseh državah članicah v skladu s členom 16(3) Direktive 98/8/ES zagotovi, da se izdajo, spremenijo ali razveljavijo dovoljenja za biocidne pripravke, ki se uporabljajo kot pripravki za zaščito lesa in vsebujejo etofenproks.
Authorisations for products to be used year-round will require the submission of dermal absorption data in order to demonstrate that the products can be used without unacceptable risks to human health.
Za izdajo dovoljenj za pripravke, namenjene celoletni uporabi, je treba predložiti podatke o dermalni absorpciji, ki dokazujejo, da se lahko pripravki uporabljajo brez nesprejemljivih tveganj za zdravje ljudi.
In the light of the findings of the assessment report, and in particular of the risk identified for workers, it is appropriate to require that products containing etofenprox and intended for industrial use as wood preservatives be used with appropriate protective equipment.
Glede na ugotovitve poročila o oceni in zlasti ugotovljenega tveganja za delavce, je primerno zahtevati, da je treba pripravke, ki vsebujejo etofenproks in se v industriji uporabljajo za zaščito lesa, uporabljati z ustrezno zaščitno opremo.
It is therefore appropriate that Member States pay particular attention to the risks to the compartments and populations that have not been representatively addressed in the Community level risk assessment and, when granting product authorisations, ensure that appropriate measures are taken or specific conditions imposed in order to mitigate the identified risks to acceptable levels.
Zato je primerno, da so države članice zlasti pozorne na tveganja za predele in prebivalce, ki niso bili reprezentativno obravnavani v oceni tveganja na ravni Skupnosti, ter da pri izdaji dovoljenj za pripravke zagotovijo, da se sprejmejo ustrezni ukrepi ali naložijo posebni pogoji za zmanjšanje ugotovljenih tveganj na sprejemljivo raven.
It is important that the provisions of this Directive be applied simultaneously in all the Member States in order to ensure equal treatment of biocidal products on the market containing the active substance etofenprox and also to facilitate the proper operation of the biocidal products market in general.
Pomembno je, da se določbe te direktive uporabljajo hkrati v vseh državah članicah, da se zagotovi enako ravnanje z biocidnimi pripravki na trgu, ki vsebujejo aktivno snov etofenproks, in da se omogoči ustrezno delovanje trga biocidnih pripravkov na sploh.
After inclusion, Member States should be allowed a reasonable period to implement Article 16(3) of Directive 98/8/EC, and in particular, to grant, modify or cancel authorisations of biocidal products in product type 8 containing etofenprox to ensure that they comply with Directive 98/8/EC.
Državam članicam je treba po vključitvi zagotoviti ustrezno obdobje za izvedbo člena 16(3) Direktive 98/8/ES in zlasti za izdajo, spremembo ali razveljavitev dovoljenj za biocidne pripravke v 8. vrsti izdelkov, ki vsebujejo etofenproks, da se zagotovi njihova skladnost z Direktivo 98/8/ES.
The following entry ‘No 5’ is inserted in Annex I to Directive 98/8/EC:
V Prilogo I k Direktivi 98/8/ES se vstavi naslednji vnos „št. 5“:
3-phenoxybenzyl-2-(4-ethoxyphenyl)-2-methylpropylether
3-fenoksibenzil-2-(4-etoksifenil)-2-metilpropileter
EC No: 407-980-2
št. ES: 407-980-2
CAS No: 80844-07-1
št. CAS: 80844-07-1
When assessing, in accordance with Article 5 and Annex VI, the application for authorisation of a product, Member States shall access those use and/or exposure scenarios and/or populations that have not been representatively addressed in the Community level risk assessment and that may be exposed to the product.
Države članice pri ocenjevanju vlog za izdajo dovoljenja za pripravek v skladu s členom 5 in Prilogo VI ocenijo tiste scenarije uporabe in/ali izpostavljenosti in/ali osebe, ki niso bili reprezentativno obravnavani v oceni tveganja na ravni Skupnosti in bi lahko bili izpostavljeni pripravku.
In view of the risk identified for workers, products cannot be used year round unless dermal absorption data is provided to demonstrate that there are no unacceptable risks from chronic exposure.
Zaradi ugotovljenega tveganja za delavce se pripravki ne smejo uporabljati vse leto, razen če predloženi podatki o dermalni absorpciji ne pokažejo, da kronična izpostavljenost ne pomeni nesprejemljivih tveganj.
In addition, products intended for industrial use must be used with appropriate personal protective equipment.’
Poleg tega je treba pripravke, namenjene uporabi v industriji, uporabljati z ustrezno osebno zaščitno opremo.“
For the implementation of the common principles of Annex VI, the content and conclusions of assessment reports are available on the Commission website: http://ec.europa.eu/comm/environment/biocides/index.htm
Za izvajanje splošnih načel Priloge VI so vsebina in sklepne ugotovitve poročil o oceni na voljo na naslednji spletni strani Komisije: http://ec.europa.eu/comm/environment/biocides/index.htm
Commission Directive 2008/17/EC
Direktiva Komisije 2008/17/ES
of 19 February 2008
z dne 19. februarja 2008
amending certain Annexes to Council Directives 86/362/EEC, 86/363/EEC and 90/642/EEC as regards maximum residue levels for acephate, acetamiprid, acibenzolar-S-methyl, aldrin, benalaxyl, benomyl, carbendazim, chlormequat, chlorothalonil, chlorpyrifos, clofentezine, cyfluthrin, cypermethrin, cyromazine, dieldrin, dimethoate, dithiocarbamates, esfenvalerate, famoxadone, fenhexamid, fenitrothion, fenvalerate, glyphosate, indoxacarb, lambda-cyhalothrin, mepanipyrim, metalaxyl-M, methidathion, methoxyfenozide, pymetrozine, pyraclostrobin pyrimethanil, spiroxamine, thiacloprid, thiophanate-methyl and trifloxystrobin
o spremembi nekaterih prilog k direktivam Sveta 86/362/EGS, 86/363/EGS in 90/642/EGS glede mejnih vrednosti ostankov acefata, acetamiprida, acibenzolar-S-metila, aldrina, benalaksila, benomila, karbendazima, klormekvata, klorotalonila, klorpirifosa, klofentezina, ciflutrina, cipermetrina, ciromazina, dieldrina, dimetoata, ditiokarbamatov, esefenvalerata, famoksadona, fenheksamida, fenitrotiona, fenvalerata, glifosata, indoksakarba, lambda-cihalotrina, mepanipirima, metalaksil-M, metidationa, metoksifenozida, pimetrozina, piraklostrobina, pirimetanila, spiroksamina, tiakloprida, tiofanat-metila in trifloksistrobina
MRLs for pesticides covered by Directive 90/642/EEC, 86/363/EEC and 86/362/EEC are to be kept under review and may be modified to take account of new or changed uses.
Mejne vrednosti ostankov za pesticide iz direktiv 90/642/EGS, 86/363/EGS in 86/362/EGS je treba pregledovati in jih je mogoče spremeniti, da se upoštevajo nove ali spremenjene rabe.